← FDA DRUG APPROVALS

FDA NDA · NDA219469

LYNKUET

elinzanetant

Sponsor: BAYER HLTHCARE

APPLICATION
NDA219469
TYPE
NDA
ORIGINAL APPROVAL
2025-10-24
LATEST ACTION
2025-10-24
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

LYNKUET · ReferencePrescription
ELINZANETANT 60MG · CAPSULE · ORAL

Approval history

2025-10-24Type 1 - New Molecular Entity · Original · standardLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →